NAD+ Precursor Complex.

NMN is the direct one-step precursor of NAD through NMN adenylyltransferase, sitting immediately upstream in the same salvage route. Formulas often carry both to enter the route at two points.

NR is phosphorylated by nicotinamide riboside kinase to NMN and then on to NAD, a route that does not depend on the rate-limiting NAMPT step. It is a parallel entrance to the same pool.

Nicotinic acid enters NAD synthesis through the separate Preiss-Handler pathway, which is intact even when the salvage route is loaded. It is the oldest and cheapest way to raise the pool.

Nicotinamide is the base that NAMPT converts back to NMN, closing the salvage loop after NAD is consumed by signalling enzymes. It is the recycled form the whole system is built around.

NADH is the reduced partner of NAD in every dehydrogenase reaction, and the ratio between the two, not the total, is what most metabolic enzymes read. They are two states of one molecule.

Tryptophan is converted through the kynurenine route to quinolinic acid and then into NAD, the only pathway that makes the coenzyme from scratch rather than recycling it. Roughly sixty milligrams of tryptophan yields one milligram of niacin equivalent.

Surplus nicotinamide is disposed of by NNMT, which spends a methyl group from S-adenosylmethionine on every molecule it clears. Betaine restores methionine from homocysteine and so replenishes the methyl pool that clearance draws down.

5-MTHF hands a methyl group to homocysteine through methionine synthase, rebuilding S-adenosylmethionine after nicotinamide methylation consumes it. It is the folate-side partner to betaine on the same cycle.

Methionine synthase cannot move the methyl group from folate to homocysteine without a cobalamin cofactor, so B12 status gates the whole regeneration step. Folate and B12 fail together on this reaction.

Apigenin inhibits CD38, one of the main enzymes that cleaves NAD, so less of the pool is consumed for the same synthesis rate. It works on the loss side rather than the supply side.

Quercetin also inhibits CD38 activity, sparing NAD from hydrolysis. Pairing a degradation brake with a precursor is the standard way these formulas are built.

Sirtuins use NAD as a stoichiometric substrate for every deacetylation they perform, so sirtuin activators only have room to work when the pool is stocked. Precursor and activator are a supply-and-demand pair.

Pterostilbene carries two methoxy groups in place of hydroxyls, which raises its oral availability while keeping the sirtuin-facing activity. It is the pairing used in most commercial NAD precursor products.

Complex I strips electrons from NADH and passes them to ubiquinone, so CoQ10 is the immediate downstream carrier in the same electron chain.

Dihydrolipoamide dehydrogenase regenerates lipoamide by handing its electrons to NAD, so the two work in the same reaction inside pyruvate and ketoglutarate dehydrogenase. Lipoate cannot cycle without NAD present.

Ribose-5-phosphate is converted to PRPP, which donates the ribose phosphate that nicotinamide and nicotinic acid are attached to during NAD assembly. It feeds the sugar half of the molecule rather than the vitamin half.

Kynureninase, the enzyme that converts 3-hydroxykynurenine to 3-hydroxyanthranilate on the way from tryptophan to NAD, is a pyridoxal-5-phosphate enzyme. When B6 is short, kynurenine intermediates divert away from the NAD branch. That makes B6 status a gate on the de novo route, which is settled biochemistry rather than a supplement claim.

Kynurenine monooxygenase uses FAD, which is built from riboflavin, to hydroxylate kynurenine. Without it the pathway to quinolinate and then NAD is interrupted. Riboflavin is therefore a second cofactor gate on the same branch a precursor complex is trying to feed.

Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase are haem enzymes and they catalyse the first step from tryptophan into the kynurenine pathway. Iron status therefore sits at the entrance of the de novo NAD route. This describes a dependency, not a reason to add iron.

Converting a precursor such as nicotinamide mononucleotide into NAD requires an ATP-dependent adenylyl transfer, and ATP works as its magnesium complex. NAD kinase, which makes NADP, is magnesium dependent as well. Every precursor in a complex passes through a magnesium-requiring step.

Alcohol and retinol dehydrogenases are zinc metalloenzymes that use NAD as their hydride acceptor. Raising precursor intake does nothing for those reactions if the catalytic zinc is not there. The relationship is enzymology, downstream of the precursor question.

Pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase both need thiamine pyrophosphate and both transfer electrons onto NAD+. A larger NAD+ pool is only used at those steps if the thiamine cofactor is present. Standard biochemistry, not a dosing claim.

Coenzyme A, built from pantothenic acid, accepts the acetyl group in the pyruvate dehydrogenase reaction that reduces NAD+. The two cofactors work in the same complex. This is pathway architecture that a precursor formula sits upstream of.

Glutathione reductase returns oxidised glutathione to its reduced form using NADPH, which is made from NAD by NAD kinase and regenerated through the pentose phosphate pathway. The NAD pool therefore sits upstream of glutathione turnover. The connection is biochemical and does not by itself predict a measured antioxidant result.

NAC provides cysteine, the rate-limiting amino acid for glutathione synthesis, while NAD-derived NADPH powers the recycling of that glutathione. One supplies the molecule and the other supplies the reducing power. The two sides have not been tested together as a combination.

CD38 is the main NAD-consuming glycohydrolase and luteolin inhibits it in enzyme and cell assays. Slowing consumption is a different lever from adding precursor. The work is preclinical, so this is a mechanistic rationale rather than a human finding.

Urolithin A promotes mitophagy in preclinical models, clearing damaged mitochondria. Precursor complexes aim at the redox cofactor those mitochondria run on. The two levers are complementary on paper and have not been co-administered in a published human trial.

Spermidine induces autophagy in cell and animal models, and NAD-dependent sirtuins are also linked to autophagy regulation. The overlap is why the two appear in the same formulas. It is preclinical convergence, not measured human synergy.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which spends a methyl group from S-adenosylmethionine. Folate, along with B12 and betaine, is part of the system that regenerates that methyl supply. This is the biochemical reason methyl donors are conventionally formulated alongside high-dose nicotinamide precursors.